Add dupilumab and mepolizumab to the toolbox for patients with chronic obstructive pulmonary disease and type 2 inflammation

Read full text Summarise with VIRAT
Authors: Thomas B. Burgess, Connie Kang
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide. A subset of patients with COPD have pulmonary type 2 inflammation, creating an opportunity for a personalised medicine approach in these individuals. Dupilumab and mepolizumab are approved for the management of COPD with type 2 inflammation, while ensifentrine is approved for use in a broader COPD population. Several more biological therapies (including tezepemulab, tozorakimab and itepekimab) remain under investigation for COPD with type 2 inflammation.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Asthma and respiratory diseases Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
Drugs & Therapy Perspectives
Volume
42
Issue
1
Pages
114–117
Publication date
26 March 2026
Language
EN